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Abstract
Aim: To investigate the effect of diabetes duration on glycaemic control, measured
using mean glycated haemoglobin (HbA1c) level, and mortality risk within different
age, sex and clinically relevant, comorbidity-defined subgroups in an elderly popula-
tion with type 2 diabetes (T2D).
Methods: We studied older (≥65 years) primary care patients with T2D, who had
three successive annual measurements of HbA1c taken between 2005 and 2013.
The primary exposure was the mean of all three HbA1c measurements. Follow-up
began on the date of the third measurement. Individual mean HbA1c levels were cat-
egorized into clinically relevant groups (<6.5% [<48 mmol/mol]; 6.5%-6.9%
[48-52 mmol/mol]; 7%-7.9% [53-63 mmol/mol]; 8%-8.9% [64-74 mmol/mol]; and
≥9% [≥75 mmol/mol]). We used multiple Cox regression to study the effect of
glycaemic control on the hazard of all-cause mortality, adjusted for age, sex, use of
concomitant medication, and age- and disease-related comorbidities.
Results: A total of 9734 individuals were included. During a median (interquartile range)
follow-up of 7.3 (4.6-8.7) years, 3320 individuals died. We found that the effect of mean
HbA1c on all-cause mortality depended on the duration of diabetes (P for interaction
<.001). For individuals with short diabetes duration (<5 years), the risk of death increased
with poorer glycaemic control (increasing HbA1c), whereas for individuals with
longstanding diabetes (≥5 years), we found a J-shaped association, where a mean HbA1c
level between 6.5% and 7.9% [48 and 63 mmol/mol] was associated with the lowest risk
of death. For individuals with longstanding diabetes, both low (<6.5% [<48 mmol/mol];
hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.07-1.37, P = .002) and high mean
HbA1c levels (≥9.0% [≥75 mmol/mol]; HR 1.60, 95% CI 1.28-1.99, P < .001) were associ-
ated with an increased risk of death. We also calculated 5-year absolute risks of all-cause
mortality, separately for short and long diabetes duration, and found similar risk patterns
across different age groups, sex and comorbidity strata.
Conclusions: In elderly individuals with T2D, the effect of glycaemic control (mea-
sured by HbA1c) on all-cause mortality depended on the duration of diabetes. Of
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particular clinical importance, we found that strict glycaemic control was associated
with an increased risk of death among individuals with long (≥ 5 years) diabetes dura-
tion. Conversely, for individuals with short diabetes duration, strict glycaemic control
was associated with the lowest risk of death. These results indicate that tight glyce-
mic control may be beneficial in people with short duration of diabetes, whereas a
less stringent target may be warranted with longer diabetes exposure.
K E YWORD S
death, elderly, hypoglycaemia, optimal glycaemic target, overtreatment, type 2 diabetes,
variability
1 | INTRODUCTION
Up to one in four older adults (≥ 65 years) have type 2 diabetes
(T2D),1 and with the overall aging of the population, this number is
likely to increase.2 Compared with older individuals without diabetes,
those with T2D are at increased risk of premature death,3 functional
disabilities,4 hypertension,5 coronary heart disease,6 stroke,6 and
other geriatric comorbidities, including cognitive impairment,7
depression,8 falls,9 polypharmacy10 and hypoglycaemia.11
Despite the considerable burden of T2D in older adults, little is
known about the specific risks and benefits associated with glycated
haemoglobin (HbA1c) targets in older adults. This lack of evidence is
partly attributable to the historical exclusion of older adults from clini-
cal trials.12 The UK Prospective Diabetes Study selectively excluded
patients aged >65 years.13 Although subsequent major clinical trials
included individuals aged >65 years, the number of individuals aged
>75 years at the time of enrolment was limited.14-16 Moreover, there
is a considerable heterogeneity in overall health status within the
elderly, making it difficult to develop “one-size-fits-all” standards for
the growing older community. Thus, clinical decision-making in older
adults relies heavily on expert opinion and extrapolation of evidence
from clinical trials of younger and healthier patients.17
Guidelines on diabetes care from multiple clinical organizations have
all adopted the concepts of individualized glycaemic targets and care
management by weighing treatment benefits against age, life expectancy,
burden of comorbidity, functional and cognitive impairment. Although
guidelines agree on individualization, they differ in the details of their rec-
ommendations, in terms of patient categories and glycaemic targets.18-23
Using a large contemporary primary care cohort of older adults
with T2D, we aimed to investigate the effect of diabetes duration on
glycaemic control and mortality risk, within different age, sex and clin-
ically relevant comorbidity-defined subgroups.
2 | METHODS
2.1 | Study population
Until 2015, general practitioners working in the Copenhagen munici-
pality and the former Copenhagen county referred their patients for
blood sampling at one core facility (the Copenhagen General Practi-
tioner's Laboratory; CGPL). From the CGPL, we identified all patients
with T2D aged ≥65 years, who had three annual HbA1c measure-
ments taken between 1 January 2005 and 31 December 2013. Indi-
viduals were included if they, in addition to the first HbA1c
measurement, had two consecutive annual measurements of HbA1c,
one after 1 year (±4 months) and another after 2 years (± 4 months).
The baseline date for follow-up was set at the third measurement of
HbA1c. For each individual, we defined our primary exposure as the
mean HbA1c of the three measurements (Figure S1). A flowchart of
study inclusion and exclusion criteria is provided in Figure S2. Individ-
uals were categorized into clinically relevant mean HbA1c groups of
<6.5% (<48 mmol/mol), 6.5%-6.9% (48 to 52 mmol/mol), 7%-7.9%
(53 to 63 mmol/mol), 8%-8.9% (64 to 74 mmol/mol) and ≥9%
(≥75 mmol/mol).
2.2 | HbA1c assays
Three commercially available assays were used to measure HbA1c in
blood: the immunoassay Tina-quant Hemoglobin A1c II on a Roche
Hitachi 911 Chemistry Analyser (Roche Diagnostics A/S, Hvidovre,
Denmark); the immunoassay Advia 1650 (Bayer, Siemens, Healthcare
Diagnostics, Tarrytown, New York); and the high-performance liquid
chromatography-based assay Tosoh G7 and G8 (Tosoh Bioscience,
Tokyo, Japan). All three assays were standardized according to the
National Glycohaemoglobin Standardization Program (NGSP). The
master equation NGSP = [0.09148 * International Federation of Clini-
cal Chemistry and Laboratory Medicine (IFCC)] + 2.152 was used to
convert NGSP (% HbA1c) results to mmol HbA1c per mol HbA, as rec-
ommended by the IFCC. The Hitachi assay was used before
December 2, 2002. The interserial coefficient of variation for the
assay was 5.8% (at level 39 mmol/mol) and 5.2% (at level 78 mmol/
mol), respectively. The correlation between the Hitachi and Advia
assays was investigated by parallel analysis of 50 human blood sam-
ples during a period of 5 days in October 2002, and this confirmed
the standardization of the assays. The Advia assay was used from
2 December 2002 until 25 January 2010 and the Tosoh assay after
25 January 2010 as described in detail by Borg et al.24
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2.3 | Data sources
Citizens with a permanent address in Denmark are assigned a unique
civil registration number, which allows linkage on an individual-level
to nationwide administrative registries. The National Population Reg-
istry contains information on sex, date of birth, date of emigration and
date of death.25 The Danish National Patient Registry holds informa-
tion on all hospitalizations, outpatient clinic and emergency room
admissions.26 When patients are discharged from the hospitals, con-
tacts are registered with a primary discharge diagnosis, and subse-
quently classified according to the 10th revision of the International
Classification of Disease (ICD-10). The Danish National Prescription
Registry contains individual-level records on dispensing date, strength,
quantity and drug type (using the Anatomical Therapeutic Chemical
System), on all claimed drug prescriptions dispensed from pharmacies
in Denmark.27 Using these registries, we attained information on
comorbidity, concomitant drug therapy, and outcomes. The cause of
death, classified using ICD-10 codes, was extracted from the Danish
Register of Causes of Death.28 In accordance with Danish law, no
approval from an ethics committee was needed in this registry-based
study with no active participation from study subjects. The use of de-
identified registry data was approved by the Danish Data Protection
Agency (record number 2007-58-0015).
2.4 | Baseline variables and endpoints
Using the aforementioned nationwide administrative registries, we
identified individuals with T2D, defined by a registry diagnosis of T2D
and/or redeemed prescription of an oral antidiabetic drug or insulin.
This definition has previously been shown to have a positive predictive
value of 97%.29 Individuals with a registry diagnosis of type 1 diabetes
were excluded. For each individual, the following comorbidities were
identified by discharge diagnoses prior to baseline: macrovascular dis-
ease, microvascular disease, atrial fibrillation, hypertension, congestive
heart failure, chronic obstructive pulmonary disease (COPD), depres-
sion, dementia, cancer without metastases, cancer with metastases,
arthritis, urinary incontinence, falls, treatment with dialysis, alcohol-
related contacts, as well as a registry diagnosis for obesity.
Macrovascular disease was defined as a composite variable defined
from discharge diagnoses of ischaemic stroke, myocardial infarction,
peripheral vascular disease or from interventions, such as percutaneous
coronary intervention, coronary artery bypass grafting or peripheral
revascularization. Microvascular disease was defined as a composite
variable based on discharge diagnoses of diabetic retinopathy or treat-
ment with laser photocoagulation, mono- or polyneuropathy, end-stage
renal disease or estimated glomerular filtration rate (eGFR) < 30 mL/
min/1.73 m2. To account for renal impairment, we used the last creati-
nine measurement obtained within 1 year prior to baseline. Creatinine
was converted to eGFR, using the Modification of Diet in Renal Disease
equation (eGFR [mL/min/1.73 m2] = 175 × [creatinine/88.4]–1.154 ×
[age]–0.203 × [0.742 if female]).30 Renal impairment was categorized as:
stages 1 and 2: eGFR ≥ 60 mL/min/1.73 m2; stage 3A: eGFR 45 to
59 mL/min/1.73 m2; stage 3B: eGFR 30 to 44 mL/min/1.73 m2; and
stages 4 and 5: eGFR ≤29 mL/min/1.73 m2. Fall traumas needing medi-
cal assistance was used as a proxy for frailty, and defined as discharge
diagnoses of contusions or fractures of the head, upper or lower
extremities within 5 years prior to baseline. Diabetes duration was cate-
gorized into levels of short (<5 years) and long (≥ 5 years) duration.
Diagnoses and procedure codes are listed in Table S1. Use of pharma-
cotherapy was defined as one or more claimed prescribed drugs within
6 months prior to baseline. Individuals with multiple prescriptions (poly-
pharmacy) were categorized into three groups (0-3, 4-5, ≥6 prescribed
drugs). Treatment with the following drugs was assessed: antidiabetic
medication; anti-hypertensive medications; antithrombotic medications;
oral anticoagulant therapy; and statins. A detailed description of codes
used to define concomitant pharmacological treatment is listed in
Table S2. We defined hypertension as a registry diagnosis of hyperten-
sion or concomitant treatment with two or more types of anti-
hypertensive drugs, as done previously.31 The primary endpoint of
interest was death from any cause. Secondary endpoints were death
from cardiovascular disease and non-cardiovascular disease.
2.5 | Classification of comorbidity burden
In the most recent American Diabetes Association (ADA) and American
Geriatric Society (AGS) guidelines, individual glycaemic targets are
advised according to the number and severity of specific medical com-
plexities listed in the guidelines.18 By adopting the ADA/AGS guide-
lines, we constructed a modified ADA/AGS three-tier comorbidity
classification.18 Individuals were classified as “healthy”, if they had at
most two of the chronic comorbidities listed in Table S3, as having
“moderate” comorbidity if they had three to five chronic comorbidities,
and lastly, as having “severe” comorbidity, if they had at least six
chronic comorbidities and/or had metastatic cancer disease, dementia
and/or chronic kidney disease requiring dialysis, as described in the
ADA/AGS guidelines.18 We did not have data on staging with respect
to heart failure and pulmonary disease, or data on functional status.
2.6 | Statistical analyses
Baseline characteristics of the study cohort were expressed as number
(proportion), mean (SD) or median (interquartile range [IQR]), where
appropriate. We used multiple Cox regression to study the effect of
glycaemic control on the hazard of all-cause and cause-specific mortal-
ity. Three different models were used to calculate the hazard ratios
(HRs). In model 1, we adjusted for baseline age group (65-70 years,
70-75 years and >75 years) and sex. In model 2, we additionally
adjusted for prevalent comorbidity (macrovascular disease, microvascu-
lar disease, atrial fibrillation, hypertension, congestive heart failure,
COPD, depression, dementia, arthritis, urinary incontinence, falls, treat-
ment with dialysis, cancer with and without metastases, alcohol-related
diagnoses and obesity) and calendar year at baseline (third measure-
ment), to account for changes in healthcare delivery over time. Model
3 represented the fully adjusted model, where we additionally adjusted
for concomitant medication (antithrombotic medication, anticoagulant
therapy, lipid-lowering medication, antidiabetic medication). Use of
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antidiabetic medication was analysed as independent variables: metfor-
min, sulphonylureas and insulin (treatment vs. no treatment). Treat-
ment with α-glucosidase inhibitors, thiazolidinediones and newer drug
classes, such as incretin drugs and selective glucose reuptake inhibitors,
were categorized as one group, as the drug exposure for these drugs
was negligible during the study period (Table S2). The mean HbA1c cat-
egory with the lowest hazard was selected as reference. Time zero for
all time-to-event analyses was the date of third HbA1c measurement
(baseline). Individual follow-up ended in case of death, emigration from
Denmark, or at 31 December 2015, whichever occurred first. We also
constructed a risk chart, displaying the 5-year absolute risks of all-
cause mortality for different combinations of age groups, sex and medi-
cal complexities, by mean HbA1c categories. Risk charts were sepa-
rately reported for short and long diabetes duration and predicted
using Cox regression.
2.7 | Sensitivity analyses
To test the robustness of our results, we conducted a number of sen-
sitivity analyses. First, to evaluate the functional relationship between
mean HbA1c and diabetes duration, we constructed a two-
dimensional contour plot, based on restricted cubic splines using Cox
regression. We modelled an interaction term between mean HbA1c
and diabetes duration, considering both as continuous variables
instead of categories. Knots were set at the 5th, 50th and 95th per-
centiles. Second, to test whether any association was dependent on
the number of measurements, we conducted additional analyses using
one or two (±4 months) annual measurements only, respectively.
Third, to test whether a more strict or liberal time-related inclusion
yielded similar results, we included individuals with three HbA1c mea-
surements, annually spaced ±3 and ± 5 months, respectively. Fourth,
as an alternate measure for glycaemic control, we tested whether the
use of the last HbA1c (third measurement) instead of the mean
HbA1c yielded comparable results. Fifth, to further explore whether
any association with mortality could be confounded by
hypoglycaemia, we adjusted the main model for hypoglycaemic events
prior to baseline. Last, recent evidence suggests that variability, that
is, glycaemic fluctuations over time, provides additional prognostic
information, independent of glycaemic control, with regard to mortal-
ity in patients with T2D.32,33 To address the effect of variability on
the association between mean HbA1c and mortality risk, we adjusted
the main models for HbA1c variability. Variability was defined as the
standard deviation of the residuals, obtained using linear regression
on the three measurements, as has been done previously
(Figure S1).31 Variability was categorized into tertiles (low, moderate
and high variability). We also accounted for the overall trend in HbA1c
by adjusting for the slope (beta) estimate, which was also categorized
into tertiles (decreasing, stable and increasing trend).
Potential effect modifications between mean HbA1c levels and
outcome hazard rates by age groups, sex, diabetes duration and
comorbidity burden, were evaluated using likelihood ratio tests com-
paring the main model to a model containing the interaction term. A
two-sided P value <.05 was taken to indicate statistical significance.
The R statistical program (R Foundation, version 3.3.3, available at
http://www.r-project.org) and R libraries: survival, rms (version 5.3),
riskRegression (version 29 January 2019), Publish (version 6 April
2018), forestplot (version 1.9), ggplot2 (version 2.2.1) were used for
all statistical analyses and graphical presentations.
3 | RESULTS
3.1 | Baseline demographics and clinical
characteristics
We identified 9734 individuals with T2D aged ≥65 years, who had
three successive annual HbA1c measurements. The baseline clinical
characteristics of the study population, grouped by diabetes duration,
are provided in Table 1. The median (IQR) age of the population at
baseline was 73.5 (69.0-79.3) years, with a similar proportion of
women and men. Just over half of the individuals (52.0%) had a mean
HbA1c level 6.5% (<48 mmol/mol). Individuals with longstanding dia-
betes had higher levels of HbA1c, were older, were more often pre-
scribed sulphonylureas and insulin and had more severe comorbidity,
such as late diabetic complications and cardiovascular disease.
3.2 | Short diabetes duration (<5 years), glycaemic
control and risk of all-cause mortality
During a median (IQR) follow-up time of 7.3 (4.6-8.7) years, 3320 indi-
viduals died. We found that the association between mean HbA1c
and the hazard of all-cause mortality depended on the duration of dia-
betes (P for interaction <.001). In the short diabetes duration group,
1578 deaths occurred during follow-up, of which 405 were deaths
from cardiovascular causes, and 1173 were deaths from non-
cardiovascular causes, respectively. For individuals with short diabetes
duration, the hazard of all-cause mortality increased in a stepwise
manner, with the lowest hazard associated with mean HbA1c <6.5%
(<48 mmol/mol; Figure 1A, model 1). The point estimates were
slightly attenuated, when we adjusted for disease- and age-related
comorbidity and concomitant medication. However, we observed a
similar dose-response relationship, with the highest hazard for all-
cause mortality associated with mean HbA1c levels of 8.0%-8.9%
(64 to 74 mmol/mol; HR 1.50, 95% CI 1.18-1.90, P < .001[Figure 1A,
model 3]). We also calculated 5-year absolute risks of all-cause mor-
tality (Figure 2), and found that the risk of all-cause mortality
increased with increasing levels of HbA1c, irrespective of age, sex and
comorbidity strata. When evaluating the relationship between levels
of glycaemia and diabetes duration as continuous variables, we found
that the hazard of death increased with increasing levels of glycaemia
for individuals with shorter diabetes duration (Figure 3). A similar pat-
tern of association with overall higher point estimates was observed
for non-cardiovascular deaths. For cardiovascular deaths, the direction
of effect was similar to the main model, albeit with none of the associ-
ations reaching statistical significance (Figure 4). We found no effect
modification with respect to age, sex or comorbidity (P for interac-
tion >.05).
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TABLE 1 Baseline characteristics of the study cohort
Diabetes duration
Total population Short duration (<5 y) Long duration (≥5 y)
Characteristics n = 9734 n = 6072 n = 3662 P
HbA1c category, n (%)
6.5% (<48 mmol/mol) 5064 (52.0) 3751 (61.8) 1313 (35.9) <.001
6.5%-6.9% (48-52 mmol/mol) 1961 (20.1) 1173 (19.3) 788 (21.5)
7.0%-7.9% (53-63 mmol/mol) 1856 (19.1) 843 (13.9) 1013 (27.7)
8.0%-8.9% (64-74 mmol/mol) 575 (5.9) 212 (3.5) 363 (9.9)
9% (≥75 mmol/mol) 278 (2.9) 93 (1.5) 185 (5.1)
Median (IQR) diabetes duration, y 3.2 (2.2-7.7) 2.3 (2.1-3.0) 9.3 (6.9-11.9) <.001
Calendar period (tertiles), y
Q1 (2006-2007) 4288 (44.1) 1719 (28.3) 2569 (70.2) <.001
Q2 (2008-2010) 2771 (28.5) 1938 (31.9) 833 (22.7)
Q3 (2011-2013) 2675 (27.5) 2415 (39.8) 260 (7.1)
Demographics
Median (IQR) age, y 73.5 (69.0-79.3) 72.9 (68.6-78.4) 74.7 (69.7-80.6) <.001
Male, n (%) 4874 (50.1) 3024 (49.8) 1850 (50.5) .507
Medication
Glucose-lowering drugs, n (%)
Insulin 520 (5.3) 82 (1.4) 438 (12.0) <.001
Metformin 3585 (36.8) 2548 (42.0) 1037 (28.3) <.001
Sulphonylureas 1453 (14.9) 793 (13.1) 660 (18.0) <.001
Other OAD 311 (3.2) 167 (2.8) 144 (3.9) .002
Number of glucose lowering drugs, n (%)
0 4438 (45.6) 2721 (44.8) 1717 (46.9)
1 4744 (48.7) 3115 (51.3) 1629 (44.5)
2 532 (5.5) 233 (3.8) 299 (8.2)
≥3 20 (0.2) 3 (0.1) 17 (0.4)
Anti-hypertensive drugs, n (%)
RAS inhibitors 1944 (20.0) 1207 (19.9) 737 (20.1) .787
Beta blockers 1747 (17.9) 1138 (18.7) 609 (16.6) .009
Calcium antagonists 902 (9.3) 565 (9.3) 337 (9.2) .894
Loop diuretics 542 (5.6) 309 (5.1) 233 (6.4) .009
Aldosterone antagonists 340 (3.5) 193 (3.2) 147 (4.0) .034
Other drugs, n (%)
Oral anticoagulants 686 (7.0) 444 (7.3) 242 (6.6) .203
Antithrombotic drugs 1826 (18.8) 1038 (17.1) 788 (21.5) <.001
Statin 2818 (29.0) 1759 (29.0) 1059 (28.9) .976
Polypharmacy, number of drugs, n (%)
0-3 8905 (91.5) 5613 (92.4) 3292 (89.9) <.001
4-5 816 (8.4) 451 (7.4) 365 (10.0)
≥6 13 (0.1) 8 (0.1) 5 (0.1)
Medical history
Chronic kidney disease, n (%)
eGFR category ≤2 (≥ 60 mL/min/1.73 m2) 7090 (72.8) 4748 (78.2) 2342 (64.0) <.001
eGFR category 3a (45-59 mL/min/1.73 m2) 1897 (19.5) 984 (16.2) 913 (24.9)
eGFR category 3b (30-44 mL/min/1.73 m2) 630 (6.5) 297 (4.9) 333 (9.1)
eGFR category ≥4 (≤ 29 mL/min/1.73 m2) 117 (1.2) 43 (0.7) 74 (2.0)
(Continues)
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3.3 | Long diabetes duration (≥5 years), glycaemic
control and risk of all-cause mortality
For individuals with longstanding diabetes, 1742 individuals died dur-
ing follow-up, of whom 478 died from cardiovascular causes and
1264 died from non-cardiovascular causes. We found a J-shaped
association between mean HbA1c categories and all-cause mortality
across all three models (Figure 1B). We found that both the lowest
(mean HbA1c <6.5% [< 48 mmol/mol]; HR 1.21, 95% CI 1.07-1.37,
P = .002 [Figure 1B, model 3]) and the highest (mean HbA1c 9.0%
[≥ 75 mmol/mol]; HR 1.60, 95% CI 1.28-1.99, P < .001[Figure 1B,
model 3]) HbA1c categories were significantly associated with an
increased hazard of all-cause mortality. The mean HbA1c category
with the lowest hazard of all-cause mortality was 6.5%-7.9% (48 to
63 mmol/mol). For non-cardiovascular mortality, the pattern of asso-
ciation was similar to that for all-cause mortality. We found no signifi-
cant association with cardiovascular death (Figure 4), albeit the point
estimates tracked in the same direction. The lowest 5-year absolute
risk of death was also associated with mean HbA1c levels between
6.5%-7.9% (48 and 63 mmol/mol), irrespective of the degree of
comorbidity or sex and age group, with increased risks at both low
and high levels of glycaemia (Figure 2). With increasing duration of
diabetes, the hazard of all-cause mortality shifted from a linear,
towards a non-linear pattern, with the highest hazard among individ-
uals very long diabetes duration and low levels of glycaemia
(Figure 3). We found no effect modification with respect to age, sex
or comorbidity (P for interaction >.05).
TABLE 1 (Continued)
Diabetes duration
Total population Short duration (<5 y) Long duration (≥5 y)
Characteristics n = 9734 n = 6072 n = 3662 P
Hypoglycaemia, n (%) 187 (1.9) 36 (0.6) 151 (4.1) <.001
Myocardial infarction, n (%) 1390 (14.3) 795 (13.1) 595 (16.2) <.001
Stroke, n (%) 1387 (14.2) 751 (12.4) 636 (17.4) <.001
Peripheral artery disease, n (%) 536 (5.5) 275 (4.5) 261 (7.1) <.001
Diabetic neuropathy, n (%) 705 (7.2) 197 (3.2) 508 (13.9) <.001
Diabetic retinopathy, n (%) 712 (7.3) 202 (3.3) 510 (13.9) <.001
Diabetic nephropathy, n (%) 308 (3.2) 95 (1.6) 213 (5.8) <.001
Dialysis, n (%) <4 (<0.0) <4 (<0.0) <4 (<0.0) .996
Congestive heart failure, n (%) 1144 (11.8) 631 (10.4) 513 (14.0) <.001
Atrial fibrillation, n (%) 1283 (13.2) 778 (12.8) 505 (13.8) .177
Hypertension, n (%) 7406 (76.1) 4565 (75.2) 2841 (77.6) .008
COPD, n (%) 899 (9.2) 581 (9.6) 318 (8.7) .154
Dementia, n (%) 152 (1.6) 69 (1.1) 83 (2.3) <.001
Depression, n (%) 101 (1.0) 58 (1.0) 43 (1.2) .352
Arthritis, n (%) 261 (2.7) 163 (2.7) 98 (2.7) 1.00
Falls, n (%) 1053 (10.8) 596 (9.8) 457 (12.5) <.001
Urinary incontinence, n (%) 258 (2.7) 159 (2.6) 99 (2.7) .851
Cancer, n (%) 1521 (15.6) 1001 (16.5) 520 (14.2) .003
Metastatic cancer, n (%) 111 (1.1) 80 (1.3) 31 (0.8) .043
Alcohol-related contacts, n (%) 172 (1.8) 98 (1.6) 74 (2.0) .163
Obesity registry diagnosis, n (%) 876 (9.0) 501 (8.3) 375 (10.2) .001
AGS/ADA medical complexity status, n (%)
Healthy 7017 (72.1) 4560 (75.1) 2457 (67.1)
Moderate comorbidities 2372 (24.4) 1325 (21.8) 1047 (28.6)
Severe comorbidities 345 (3.5) 187 (3.1) 158 (4.3) <.001
Note: Due to Danish data protection regulation (the Act on Processing of Personal Data), any observations <4 may not be reported. Diagnoses of obesity
and alcohol were obtained from registry diagnoses.
Abbreviations: ADA, American Diabetes Association; AGS, American Geriatric Society; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular filtration rate; IQR, interquartile range; n, number of individuals; OAD, oral antidiabetic drug; RAS, renin-angiotensin system.
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3.4 | Glycaemic control by degree of comorbidity
To evaluate glycaemic control levels among older adults with T2D
by overall health status, we categorized individuals based on the
number and severity of comorbidities (Table S4). Overall, we found
that 70.7% and 69.5% of patients with moderate and severe comor-
bidity, respectively, had glycaemic levels 7% (<53 mmol/mol). We
also found that individuals with moderate and severe comorbidity
were generally older, had longer diabetes duration, and were more
often treated with multiple drugs, in particular sulphonylureas and
insulin, compared with individuals classified as healthy (Table S4). Of
those treated with glucose-lowering drugs, 19.1% and 30.9% of the
individuals classified as having severe comorbidity, were treated
with insulin and sulphonylureas, respectively. The proportion of indi-
viduals with moderate comorbidity receiving insulin corresponded to
12.9% and 30.4% for sulphonylureas. Of individuals classified as
healthy, 8.4% received insulin and 26.3% a sulphonylurea,
respectively.
3.5 | Sensitivity analyses
To test the robustness and generalizability of our associations, we
conducted seven sensitivity analyses. The results did not materially
change when modelling the exposure as a continuous variable
(Figure 3). Nor did the pattern of association change when using a
different number of measurements, different time-related cut-offs
for inclusion, an alternate exposure of HbA1c (last measurement
instead of mean HbA1c) or adjusting the main model for hyp-
oglycaemic events, HbA1c variability or trend (Figure S3). More-
over, we found that the hazard of death increased monotonically
with increasing HbA1c variability for individuals with short dura-
tion of diabetes, but not for individuals with longstanding diabetes.
Also, increasing trend compared with a stable trend in HbA1c was
associated with increased hazard of death in both individuals with
short and long duration of diabetes. However, a decreasing trend
was only associated with increased hazard in individuals with
longstanding disease.
F IGURE 1 Glycated haemoglobin (HbA1c) categories and the hazard ratio (HR) of all-cause mortality by groups of A, short (<5 years) and B,
long (≥5 years) diabetes duration. Model 1 was adjusted for age groups (65-70 years, 70-75 years and > 75 years) and sex. Model 2 was
additionally adjusted for comorbidity (macrovascular disease, microvascular disease, atrial fibrillation, hypertension, congestive heart failure,
chronic obstructive pulmonary disease, depression, dementia, cancer, arthritis, urinary incontinence, falls, treatment with dialysis, cancer with
metastases, alcohol-related diagnoses, and obesity) and calendar period. Model 3 represented the fully adjusted model, where we additionally
adjusted for concomitant medication (antithrombotic medication, anticoagulant therapy, lipid-lowering medication, and antidiabetic medication).
The solid dots refer to the HR's, and horizontal lines represent 95% confidence intervals (CI). The HbA1c category with the lowest hazard was
selected as reference
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4 | DISCUSSION
Using real-world data of older primary care patients with T2D, we
found that the association between glycaemic control and the risk of
death depended on the duration of diabetes. For individuals with
short diabetes duration (<5 years), we found that the risk of death
increased with poorer glycaemic control, whereas for individuals with
longstanding diabetes (≥5 years), we found a J-shaped association,
F IGURE 2 Five-year absolute risk prediction chart for all-cause mortality, based on individuals with A, short (<5 years) and B, long (≥5 years)
diabetes duration, and the combination of age groups, sex and comorbidity, with respect to different levels of mean glycated haemoglobin
(HbA1c, in %). Individuals were classified as healthy, if they had ≤2 comorbidities, moderate if they had three to five comorbidities, and severe, if
they had ≥6 comorbidities and/or had metastatic cancer disease, dementia, or chronic kidney disease requiring dialysis. The colour scheme refers
to the absolute 5-year risk (%) for all-cause mortality
F IGURE 3 Contour plot displaying the functional relationship between levels of mean glycated haemoglobin (HbA1c; mmol/mol and %) and
diabetes duration (years), using restricted cubic splines regression. Knots were set at the fifth, 50th and 95th percentile. A mean HbA1c value of
6.5% (48 mmol/mol) and diabetes duration of 2 years was set as reference. Only data between the 10th and 90th percentile is shown, to avoid
presenting results for mean HbA1c and diabetes duration values for which the number of observations were small. The solid lines and the colour
scheme refer to the hazard ratio (HR) for all-cause mortality. The model was adjusted as described in Figure 1 (model 3)
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with the lowest risk associated with glycaemic levels between 6.5%-
7.9% (48 and 63 mmol/mol). These results were consistent across dif-
ferent age, sex and comorbidity-defined subgroups.
Previous studies on middle-aged patients with T2D have
shown conflicting results concerning the relationship between
glycaemic control, diabetes duration and mortality risk. For
instance, in a recent study by Laiteerapong et al.34 the authors
found that newly diagnosed middle-aged patients with tight
glycaemic control (6.5% [<48 mmol/mol ]) had the lowest mortality
risk, with increasing effect sizes with longer exposure to poor
glycaemic control.34 As opposed to our results on elderly patients,
they found no increased mortality risk in the normoglycaemic
range with increasing duration of diabetes. In another, smaller
study (531 individuals) of middle-aged patients with T2D, it was
found that long diabetes duration (≥5 years) and good glycaemic
control (<6.5% [48 mmol/mol]) was associated with increased risk
of death. However, no incremental risk was observed in patients
with a combination of longstanding diabetes and higher levels of
glycaemia.35 Lastly, a duration-dependent relationship has also
been reported for cardiovascular events in a post hoc analysis of
the Veterans Affairs Diabetes Trial, where patients in the intensive
arm, who entered the trial with a diabetes duration >15 years, had a
higher risk of macrovascular events, compared with the standard arm.31
We are, to the best of our knowledge, the first to extend this duration-
dependent relationship between glycaemic control and mortality risk to
an elderly population with T2D. We are also the first to report that signifi-
cant risk exists in both the higher and lower tails of glycaemia in elderly
patients with longer diabetes exposure.
The interaction between diabetes duration and glycaemic control
on the risk of death that we report could potentially also explain the
inconsistencies between previous observational studies on older
patients with T2D, which have reported both linear32,33 and non-
linear relationships30,34,35 between levels of glycaemia and mortality
risk. Although the present study does not allow for causal inference
due to its observational design, our results suggest that aiming for
normoglycaemic levels in those with short duration of diabetes may
be beneficial, whereas for individuals with long diabetes duration, set-
ting universal goals may be less straightforward. In these patients,
additional important factors, such as frailty, life expectancy and
patient preferences should be considered, to better provide patient-
centred care that balances the pros and cons of tight glycaemic
control.
F IGURE 4 Glycated haemoglobin (HbA1c) categories and the hazard rate of cardiovascular (CVD, red) and non-cardiovascular (non-CVD,
blue) mortality by groups of A, short (<5 years) and B, long (≥ 5 years) diabetes duration. Results from the main model (Figure 1, model 3, black) is
shown for comparison. The model was adjusted as described in Figure 1 (model 3). The solid markers refer to the hazard ratios (HR), and
horizontal lines represent the 95% confidence intervals (CI). ACM, all-cause mortality
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Several factors may explain the observed mortality risk associated
with long diabetes duration and HbA1c levels in the lower region.
Hypoglycaemia is a potent candidate mechanism. We found that indi-
viduals with longstanding diabetes were more often prescribed
sulphonylureas and insulin compared with individuals with short dia-
betes duration (Table 1 and Tables S5 and S6). These drugs can by
themselves, or in concert with malnourishment, severe comorbidity,
cognitive impairment and/or polypharmacy, induce hypoglycaemia, all
of which were more prevalent in the long diabetes duration group.
Hypoglycaemia, in particular in the elderly, is important to prevent, as
it is associated with falls, cognitive impairment, hospitalizations, car-
diovascular events and mortality risk.18,36-38 Also, low levels of
glycaemia may not always be indicative of intentional good glycaemic
control, but rather a proxy for poor nutritional status and general
frailty, both of which have been associated with increased mortality
risk.39 The latter is supported by the existence of a J-shaped associa-
tion between levels of glycaemia and mortality risk in non-diabetic
populations, suggesting that non-glycaemic factors may partly explain
the observed risk in the lower glycaemic range.40
In terms of glycaemic variability, our results are in accordance with
previous studies that have shown that higher variability in HbA1c is
associated with an increased risk of mortality in patients with
T2D.33,41 However, the present study provides additional evidence
that, at least in older adults, the prognostic effect of HbA1c variability
may be specific to patients with short duration of diabetes, but not
long duration. By contrast, a decreasing trend in HbA1c in the present
study was associated with increased risk of death in patients with long
diabetes duration, but not in those with short duration. From a clinical
standpoint, variability might represent an important prognostic marker
in patients with short duration of diabetes, whereas physicians may
need to be more attentive not only to low levels of glycaemia, but also
unintentional decreasing HbA1c over time, in particular in patients
with longstanding diabetes.
In the present study, we also found signs of potential over-
treatment of older adults with T2D. Almost 70% of individuals with
moderate and severe comorbidity had tight glycaemic control (<7.0%
[<53 mmol/mol]) and, concurrently, the largest proportion of risk fac-
tors for severe hypoglycaemia (eg, older age, polypharmacy, severe
renal impairment) compared with the healthy group (Table S4). Nearly
50% of the individuals across all three tiers did not receive any
glucose-lowering drugs; however, among those who did, individuals
with moderate and severe comorbidity were more often prescribed
regimens containing insulin and sulphonylureas, compared with the
healthy group. These data indicate that guideline recommendations
may not have been fully adopted into clinical practice in Denmark,
and that a substantial proportion of patients that are traditionally con-
sidered at high risk of hypoglycaemia and other adverse effects, do
not receive appropriate de-intensification of their treatment, despite
the fact that existing recommendations in geriatric diabetes advocate
a more moderate practice in this patient group. These data comple-
ment previous concerns about the frequency of overtreatment in
older adults with T2D.42-44
We found no evidence of differences in optimal treatment targets
across the three comorbidity tiers. However, this does not invalidate
differentiated treatment goals by different comorbidity strata, as
advised by current clinical recommendations. For healthy older peo-
ple, with short diabetes duration and extended life expectancy, a
glycaemic target similar to that for younger patients (7% [<53 mmol/
mol]) may be appropriate. In accordance with our data, tight glycaemic
control may also be appropriate in patients with several comorbidities
(Figure 2), as long as it is in line with the patient's preferences and
achieved through low risk intervention, for example, lifestyle modifi-
cation and/or metformin. However, in patients with very long diabe-
tes duration, limited life expectancy, cognitive impairment and/or
functional dependencies, a conservative treatment target is
warranted, as treatment benefits are most likely outweighed by the
risk of harm. At present, only the Department of Veterans Affairs22
advocates differentiated treatment of older adults based on levels of
comorbidity and diabetes duration. Based on our results, we suggest
that other major clinical recommendations should in addition to indi-
vidual medical complexity, also consider diabetes duration as an
important discerning factor, when setting individual goals for older
patients with T2D.
The strengths of the present study include a large population-
based primary care sample of elderly patients with T2D, long-term
follow-up, and utilization of clinical and administrative registries, tak-
ing multiple disease- and age-related comorbidities into account.
Moreover, we used serial HbA1c, allowing a more detailed evaluation
of long-term glycaemic control, as well as being able to account for
the effect of temporal fluctuations in HbA1c.
Some limitations of this study should also be noted. We did not
have information on functional limitations, for example, activities of
daily living; however, our data were collected from available labora-
tory records as part of the patient's routine clinical follow-up,
suggesting that our results are most likely based on patients with a
certain degree of self-management and preserved functional abilities.
We did not have information on the indication for HbA1c testing;
thus, patients with three annual measurements could, in theory, repre-
sent a selected group of patients. We found that individuals with non-
annual measurements were slightly older, with longer duration of dia-
betes, had marginally poorer glycaemic control, more diabetes-related
late complications and other major comorbidities (Table S7). However,
we do not believe that this selection of patients has affected the gen-
eralizability of our results, as we found similar results for individuals
with one, two and three annual measurements, as well as for individ-
uals with a non-annual referral pattern.
In conclusion, this cohort study of older primary care patients
aged ≥65 years with T2D demonstrates that the risk of mortality dif-
fers by levels of glycaemia and duration of the disease. For individuals
with short diabetes duration (<5 years), we found that the risk of
death increased with poorer glycaemic control, whereas for individ-
uals with longstanding diabetes (≥5 years), we found a J-shaped asso-
ciation, with the lowest risk associated with glycaemic levels of 6.5%-
7.9% (48 to 63 mmol/mol).
240 GHOUSE ET AL.
ACKNOWLEDGMENTS
J.G. was supported by the Research Foundation at Copenhagen Uni-
versity Hospital, Rigshospitalet, Karen Marie Jespersen og Datters
Legat, the Arvid Nilsson Foundation, the John og Birthe Meyer Foun-
dation and Hallas-Møller Emerging Investigator. J.B.N. was supported
by grants from the Danish Heart Foundation (16-R107-A6779) and
the Lundbeck Foundation (R220-2016-1434), Fonden til
Lægevidenskabens Fremme (The A.P. Møller and Chastine Mc-Kinney
Møller Foundation for General Purposes), and Fondsbørsvekselerer
Henry Hansen og Hustru Karla Hansen Født Vestergaards Legat.
CONFLICT OF INTERESTS
J.G., J.L.I., M.W.S., J.K.K, B.L., M.S.O. and J.B.N. have no conflict of
interest to disclose. A.G.H. is an employee of Novo Nordisk A/S, Den-
mark. J.H.S. has received research grants from Medtronic, Biotronik
and Gilead, personal fees as speaker for Medtronic, Biotronik, Astra-
Zeneca and Boehringer Ingelheim and personal fees as a member of
an advisory committee in Medtronic.
AUTHOR CONTRIBUTIONS
J.G., J.L.I, J.K.K, M.W.S, A.G.H. and J.B.N. made primary contributions
to study conception, design, statistical analyses, interpretation of
results, and writing of the manuscript. B.L. collected the HbA1c data
and described the HbA1c assays. All authors contributed to interpre-
tation of results, all revised the manuscript critically for important
intellectual content, and all approved the final manuscript. J.B.N. is
the guarantor of this work and, as such, had full access to all the data
in the study and takes responsibility for the integrity of the data and
the accuracy of the data analysis.
DATA-SHARING
Due to Danish data protection legislation, raw data and study mate-
rials will not be made available to other researchers.
ORCID
Jonas B. Nielsen https://orcid.org/0000-0002-6654-2852
REFERENCES
1. Szoke E, Shrayyef MZ, Messing S, et al. Effect of aging on glucose
homeostasis: accelerated deterioration of beta-cell function in individ-
uals with impaired glucose tolerance. Diabetes Care. 2008;31(3):
539-543.
2. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projec-
tion of the year 2050 burden of diabetes in the US adult population:
dynamic modeling of incidence, mortality, and prediabetes preva-
lence. Popul Health Metr. 2010;8:29.
3. Tancredi M, Rosengren A, Svensson A-M, et al. Excess mortality
among persons with type 2 diabetes. N Engl J Med. 2015;373(18):
1720-1732.
4. Gregg EW, Mangione CM, Cauley JA. et al; Study of Osteoporotic
Fractures Research GroupDiabetes and incidence of functional dis-
ability in older women. Diabetes Care. 2002;25(1):61-67.
5. Ninomiya T, Zoungas S, Neal B. et al; ADVANCE Collaborative
GroupEfficacy and safety of routine blood pressure lowering in older
patients with diabetes: results from the ADVANCE trial. J Hypertens.
2010;28(6):1141-1149.
6. Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and
cardiovascular outcomes in patients with type 2 diabetes. N Engl J
Med. 2018;379(7):633-644.
7. Lu F-P, Lin K-P, Kuo H-K. Diabetes and the risk of multi-system aging
phenotypes: a systematic review and meta-analysis. PloS One. 2009;4
(1):e4144.
8. Nouwen A, Winkley K, Twisk J, et al. Type 2 diabetes mellitus as a risk
factor for the onset of depression: a systematic review and meta-
analysis. Diabetologia. 2010;53(12):2480-2486.
9. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabe-
tes have a higher risk of falls: a prospective study. Diabetes Care.
2002;25(10):1749-1754.
10. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review.
J Am Acad Nurse Pract. 2005;17(4):123-132.
11. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes:
a report of a workgroup of the American Diabetes Association and
the Endocrine Society. Diabetes Care. 2013;36(5):1384-1395.
12. Saunders C, Byrne CD, Guthrie B. et al; on behalf of the Scottish Dia-
betes Research Network Epidemiology GroupExternal validity of ran-
domized controlled trials of glycaemic control and vascular disease:
how representative are participants? Diabet Med. 2013;30(3):
300-308.
13. Intensive blood-glucose control with sulphonylureas or insulin com-
pared with conventional treatment and risk of complications in
patients with type 2 diabetes (UKPDS 33). UKprospective diabetes
study (UKPDS) group. Lancet. 1998;352(9131):837-853.
14. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Inten-
sive blood glucose control and vascular outcomes in patients with
type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
15. Action to Control Cardiovascular Risk in Diabetes Study Group,
Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in
type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
16. Duckworth W, Abraira C, Moritz T. et a; VADT InvestigatorsGlucose
control and vascular complications in veterans with type 2 diabetes.
N Engl J Med. 2009;360(2):129-139.
17. Kirkman MS, Briscoe VJ, Clark N. et al; Consensus Development Con-
ference on Diabetes and Older AdultsDiabetes in older adults: a con-
sensus report. J Am Geriatr Soc. 2012;60(12):2342-2356.
18. American Diabetes Association. 11. Older adults: standards of medi-
cal Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl. 1):S119-
S125.
19. American Geriatrics Society Expert Panel on Care of Older Adults
with Diabetes Mellitus, Moreno G, Mangione CM, Kimbro L,
Vaisberg E. Guidelines abstracted from the American Geriatrics Soci-
ety guidelines for improving the Care of Older Adults with diabetes
mellitus: 2013 update. J Am Geriatr Soc. 2013;61(11):2020-2026.
20. Cahn A, Raz I, Kleinman Y, et al. Clinical assessment of individualized
Glycemic goals in patients with type 2 diabetes: formulation of an
algorithm based on a survey among leading worldwide Diabetologists.
Diabetes Care. 2015;38(12):2293-2300.
21. Sinclair AJ, Paolisso G, Castro M. et al; European Diabetes Working
Party for Older PeopleEuropean diabetes working Party for Older
People 2011 clinical guidelines for type 2 diabetes mellitus. Executive
summary Diabetes Metab. 2011;37(Suppl. 3):S27-S38.
22. US Department of Veterans Affairs. VA/DoD Clinical Practice
Guideline for the Management of Type 2 Diabetes Mellitus in Primary
Care. https://www.healthquality.va.gov/guidelines/CD/diabetes/.
Accessed June 1, 2019.
GHOUSE ET AL. 241
23. Dunning T, Sinclair A, Colagiuri S. New IDF guideline for managing
type 2 diabetes in older people. Diabetes Res Clin Pract. 2014;103(3):
538-540.
24. Borg R, Persson F, Siersma V, Lind B, de Fine ON, Andersen CL. Interpre-
tation of HbA1c in primary care and potential influence of anaemia and
chronic kidney disease: an analysis from the Copenhagen primary care
laboratory (CopLab) database. Diabet Med. 2018;35(12):1700-1706.
25. Pedersen CB. The Danish civil registration system. Scand J Public
Health. 2011;39(7_suppl):22-25.
26. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L,
Sørensen HT. The Danish National Patient Registry: a review of content,
data quality, and research potential. Clin Epidemiol. 2015;7:449-490.
27. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescrip-
tion Registry. Scand J Public Health. 2011;39(7 Suppl):38-41.
28. Helweg-Larsen K. The Danish register of causes of death. Scand J
Public Health. 2011;39(7 Suppl):26-29.
29. Kornum JB, Thomsen RW, Riis A, Lervang H-H, Schønheyder HC.
Sørensen HT type 2 diabetes and pneumonia outcomes: a
population-based cohort study. Diabetes Care. 2007;30(9):2251-
2257.
30. Levey AS, Coresh J, Greene T. et al; for the Chronic Kidney Disease Epi-
demiology Collaboration*Using standardized serum creatinine values in
the modification of diet in renal disease study equation for estimating glo-
merular filtration rate. Ann Intern Med. 2006;145(4):247-254.
31. Ghouse J, Skov MW, Kanters JK, et al. Visit-to-visit variability of
Hemoglobin A1c in people without diabetes and risk of major adverse
cardiovascular events and all-cause mortality. Diabetes Care. 2018;42
(1):134-141.
32. Gorst C, Kwok CS, Aslam S, et al. Long-term Glycemic variability and
risk of adverse outcomes: a systematic review and meta-analysis. Dia-
betes Care. 2015;38(12):2354-2369.
33. Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA1c, HbA1c
variability, and mortality in people with diabetes aged 70 years and
older: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;
6(6):476-486.
34. Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 dia-
betes: impact of early Glycemic control on future complications (the
Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426.
35. Davis TM, Chubb SA, Bruce DG, Davis WA. Metabolic memory and all-
cause death in community-based patients with type 2 diabetes: the Fre-
mantle diabetes study. Diabetes Obes Metab. 2016;18(6):598-606.
36. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk fac-
tors for serious hypoglycemia in older persons using insulin or sulfo-
nylureas. Arch Intern Med. 1997;157(15):1681-1686.
37. Schwartz AV, Vittinghoff E, Sellmeyer DE. et al; for the Health, Aging,
and Body Composition StudyDiabetes-related complications, glycemic
control, and falls in older adults. Diabetes Care. 2008;31(3):391-396.
38. Schütt M, Fach E-M, Seufert J. et al; for the DPV Initiative and the
German BMBF Competence Network Diabetes MellitusMultiple
complications and frequent severe hypoglycaemia in “elderly” and
“old” patients with type 1 diabetes. Diabet Med. 2012;29(8):
e176-e179.
39. Vischer UM, Perrenoud L, Genet C, Ardigo S, Registe-Rameau Y,
Herrmann FR. The high prevalence of malnutrition in elderly diabetic
patients: implications for anti-diabetic drug treatments. Diabet Med.
2010;27(8):918-924.
40. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes,
and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362
(9):800-811.
41. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glyce-
mic variability on the risks of macrovascular and microvascular events
and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabe-
tes Care. 2014;37(8):2359-2365.
42. Tseng C-L, Soroka O, Maney M, Aron DC, Pogach LM. Assessing
potential glycemic overtreatment in persons at hypoglycemic risk.
JAMA Intern Med. 2014;174(2):259-268.
43. McCoy RG, Van Houten HK, Ross JS, Montori VM, Shah ND. HbA1c
overtesting and overtreatment among US adults with controlled type
2 diabetes, 2001-13: observational population based study. BMJ.
2015;351:h6138.
44. Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential
overtreatment of diabetes mellitus in older adults with tight Glycemic
control. JAMA Intern Med. 2015;175(3):356-362.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Ghouse J, Isaksen JL, Skov MW,
et al. Effect of diabetes duration on the relationship between
glycaemic control and risk of death in older adults with type 2
diabetes. Diabetes Obes Metab. 2020;22:231–242. https://doi.
org/10.1111/dom.13891
242 GHOUSE ET AL.
